Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

SISCAPA Assay Technologies Appoints Gustavo Salem as President and CEO

Published: Monday, April 28, 2014
Last Updated: Tuesday, April 29, 2014
Bookmark and Share
Gustavo has previously worked worked closely with the company to evaluate strategic opportunities in life science research.

SISCAPA Assay Technologies, Inc. today announced the appointment of Gustavo (Gus) Salem to the position of President and CEO.  For the past 18 months, Gus has served as a member of the board of directors and has worked closely with the company to evaluate strategic opportunities in the life science research and clinical diagnostics markets.

“We are extremely pleased to have Gus join the SAT team, and to drive our execution as a commercial stage company,” said Leigh Anderson, SAT’s founder, who continues as Chairman and Chief Scientific Officer.  “Gus has already brought great value as an engaged board member based on a proven track-record in building teams, developing strategy and entering new markets.  His familiarity with the company, technology and team will provide for a smooth and effective transition.”

Gus brings over 25 years of life science and health science leadership experience to the position. Previously, while VP and General Manager of the Biological Systems Division at Agilent Technologies, he managed the mass spectrometry, genomics, and clinical diagnostics businesses amounting to >$500M annual sales. During his tenure, Agilent developed into a market-leading supplier of LC/MS and established market leadership in target enrichment sample prep for next generation DNA sequencing. Gus previously served as President and CEO of Assay Designs, Inc., a venture-backed company developing immunoassays and antibody reagents (now part of Enzo Life Sciences). Prior to Assay Designs he managed the Protein Separations Division of Bio-Rad Laboratories, which included product lines for chromatography and electrophoresis instruments and consumables.

“I want to thank Leigh and my fellow board members for this opportunity.  We have identified some very exciting new diagnostic opportunities, and will continue to invest in the analytical and clinical validation of SISCAPA technology.  The company is committed to our current partners and customers in improving access to the technology, and expanding our customer base through launch of new products and services,” said Mr. Salem.  “I am very excited to lead the team as we increase our focus on lab operations and commercial activities.  We have great partners, strong revenue momentum, and an excellent strategy focused on empowering patients through improved clinical tests.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SISCAPA Assay Technologies Closes Series A Financing Round
The company will now move forward on targeting wellness and chronic disease monitoring.
Monday, May 12, 2014
Scientific News
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Novel Proteins Linked to Huntington's Disease
University of Florida Health researchers have made a new discovery about Huntington's disease, showing that the gene that causes the fatal disorder makes an unexpected "cocktail" of mutant proteins that accumulate in the brain.
Enzyme Critical to Maintaining Telomere Length Discovered
New method expected to speed understanding of short telomere diseases and cancer.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos